These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 19419924)

  • 21. [Inhibitors of the EGFR pathway in non small cell lung cancer: what's new in 2007?].
    Grenier J; Soria JC
    Bull Cancer; 2007 Jan; 94(1):53-61. PubMed ID: 17237005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
    Wheler J; Falchook G; Tsimberidou AM; Hong D; Naing A; Piha-Paul S; Chen SS; Heymach J; Fu S; Stephen B; Fok JY; Janku F; Kurzrock R
    Oncotarget; 2013 May; 4(5):772-84. PubMed ID: 23800712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.
    Chen YM
    J Chin Med Assoc; 2013 May; 76(5):249-57. PubMed ID: 23683257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.
    Gui T; Shen K
    Cancer Epidemiol; 2012 Oct; 36(5):490-6. PubMed ID: 22818908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-epidermal-growth-factor-receptor agents and complete responses in the treatment of advanced non-small-cell lung cancer: a meta-analysis of 17 phase III randomized controlled trials.
    Qi WX; Fu S; Zhang Q; Guo XM
    Curr Med Res Opin; 2015 Jan; 31(1):25-33. PubMed ID: 25329826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidermal growth factor receptor inhibition strategies in oncology.
    Harari PM
    Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of tyrosine kinase inhibitors in lung cancer.
    Ansari J; Palmer DH; Rea DW; Hussain SA
    Anticancer Agents Med Chem; 2009 Jun; 9(5):569-75. PubMed ID: 19519298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
    Yonesaka K; Zejnullahu K; Lindeman N; Homes AJ; Jackman DM; Zhao F; Rogers AM; Johnson BE; Jänne PA
    Clin Cancer Res; 2008 Nov; 14(21):6963-73. PubMed ID: 18980991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of EGFR Monoclonal Antibodies in the Management of Non-small Cell Lung Cancer.
    Takeda M; Nakagawa K
    Curr Cancer Drug Targets; 2015; 15(9):792-802. PubMed ID: 26567882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.
    Neal JW; Heist RS; Fidias P; Temel JS; Huberman M; Marcoux JP; Muzikansky A; Lynch TJ; Sequist LV
    J Thorac Oncol; 2010 Nov; 5(11):1855-8. PubMed ID: 20975380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of policy options on first-line treatments for advanced, non-small cell lung cancer in Thailand.
    Limwattananon C; Limwattananon S; Waleekhachonloet O; Rattanachotphanit T
    Lung Cancer; 2018 Jun; 120():91-97. PubMed ID: 29748023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of inhibitors of the epidermal growth factor in management of head and neck cancer.
    Brockstein B; Lacouture M; Agulnik M
    J Natl Compr Canc Netw; 2008 Aug; 6(7):696-706. PubMed ID: 18691458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
    Fan Y; Huang ZY; Yu HF; Luo LH
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer.
    Fong T; Morgensztern D; Govindan R
    J Thorac Oncol; 2008 Mar; 3(3):303-10. PubMed ID: 18317074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
    Langer CJ
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):991-1002. PubMed ID: 14967461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?
    Juergens R; Brahmer J
    Curr Oncol Rep; 2007 Jul; 9(4):255-64. PubMed ID: 17588349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ZD1839 (Iressa) in non-small cell lung cancer.
    Herbst RS; Kies MS
    Oncologist; 2002; 7 Suppl 4():9-15. PubMed ID: 12202783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
    Silvestri GA; Rivera MP
    Chest; 2005 Dec; 128(6):3975-84. PubMed ID: 16354869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidermal growth factor receptor (EGFR) inhibitors and derived treatments.
    Dziadziuszko R; Jassem J
    Ann Oncol; 2012 Sep; 23 Suppl 10():x193-6. PubMed ID: 22987961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.